Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;97(1):341-352.

Therapeutic avenues for hereditary forms of retinal blindness

Affiliations
  • PMID: 29666355
Review

Therapeutic avenues for hereditary forms of retinal blindness

Chitra Kannabiran et al. J Genet. 2018 Mar.

Abstract

Hereditary retinal diseases, known as retinal degenerations or dystrophies, are a large group of inherited eye disorders resulting in irreversible visual loss and blindness. They develop due to mutations in one or more genes that lead to the death of the retinal photoreceptor cells. Till date, mutations in over 200 genes are known to be associated with all different forms of retinal disorders. The enormous genetic heterogeneity of this group of diseases has posedmany challenges in understanding the mechanisms of disease and in developing suitable therapies. Therapeutic avenues that are being investigated for these disorders include gene therapy to replace the defective gene, treatment with neurotrophic factors to stimulate the growth of photoreceptors, cell replacement therapy, and prosthetic devices that can capture light and transmit electrical signals through retinal neurons to the brain. Several of these are in process of human trials in patients, and have shown safety and efficacy of the treatment. A combination of approaches that involve both gene replacement and cell replacement may be required for optimum benefit.

PubMed Disclaimer

References

    1. Arch Ophthalmol. 2010 Apr;128(4):403-11 - PubMed
    1. J Biol Chem. 2014 Mar 7;289(10):6362-71 - PubMed
    1. Lancet. 2014 Mar 29;383(9923):1129-37 - PubMed
    1. PLoS One. 2013 May 07;8(5):e61396 - PubMed
    1. Mol Med. 2012 Dec 06;18:1312-9 - PubMed

LinkOut - more resources